SoundHound AI Inc (SOUN) Stock Price Today
Aura AI Summary
Key Stats
- $2.45BMarket Cap
- 16,881,989Volume
- TechnologySector
- $21.4052W High
- $5.5252W Low
- 23 DaysTypical Hold Time
- $2.25BEnterprise Value
- -Div Yield
- 82% Sell | 18% BuyTrading Activity
Track SoundHound AI Inc (SOUN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, SoundHound AI Inc has traded between a low of $5.39 and a high of $21.4, highlighting its annual price range. Buy and sell SoundHound AI Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Most Recent News
ZenaTech launches AI-powered smart safety glasses Stacklens for field technicians, with pilots in 2027.
ZenaTech introduced Stacklens™, AI-powered smart safety glasses designed for field technicians and industrial workers, integrating hands-free AI assistance, real-time video support, and thermal imaging. The glasses aim to improve efficiency by allowi...

Class action lawsuit filed over Compass-Anywhere merger alleging regulatory misrepresentation.
The Rosen Law Firm has filed a class action lawsuit on behalf of former Anywhere Real Estate shareholders who received Compass, Inc. stock in a January 2026 merger. The suit alleges that Compass and its executives misrepresented their efforts to secu...

New data supports Furoscix ReadyFlow autoinjector for outpatient edema management in heart failure and CKD.
MannKind presented new clinical data at HFSA 2026 showing that Furoscix ReadyFlow, an autoinjector delivering subcutaneous furosemide, provides diuretic effects comparable to IV administration for treating edema in heart failure and chronic kidney di...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.